Spotlight: Clinicaltrials.gov Registration and Reporting Enforcement

Sep 1, 2022 | Conduits News

On July 22, 2022, the revised federal policies for ClinicalTrials.gov took effect, including new penalties for non-compliance. The financial penalty is significant ($13,237 per day of non-compliance), and existing and future NIH funding may be impacted. Specifically, the NIH has suggested that they may withhold grant awards for the entire institution in response to non-compliance. The ISMMS ClinicalTrials.gov Registration and Reporting policy requires departments to be responsible for any financial penalty incurred by their faculty member due to non-compliance.

The PI is responsible for registering the clinical trial and reporting results under the guidelines outlined in the ISMMS ClinicalTrials.gov Registration and Reporting policy.

Please note that more than 60 Pre-Notices of Non-Compliance have been sent to date. There are four notices of Non-Compliance posted on FDA.gov. If you receive a Pre-Notice letter of Non-Compliance or Letter of Non-Compliance, please contact the Office of Research Services (ORS) immediately by opening a ticket at ClinicalTrials.gov Assistance – Research 411 Portal – Jira Service Management (atlassian.net) and providing a phone number where you can be reached.

The ORS can provide support and help the PI navigate the ClinicalTrials.gov process. However, the PI is responsible for ensuring the proper registration and reporting for their clinical trial. For more information on ClinicalTrials,gov registration and reporting results, visit the Research Roadmap. If you have any questions or would like to request assistance, please contact the ORS via the Research 411 Portal

ConduITS is supported by NCATS of the NIH’s CTSA Program. Any use of CTSA-supported resources requires citation of grant number UL1TR004419 awarded to ISMMS in the acknowledgment section of every publication resulting from this support. Adherence to the NIH Public Access Policy is also required.

Recent ConduITS News

What does the Innovation Core do?

Mount Sinai’s Innovation Core is designed to fill the gap in the training and expertise needed to move a discovery from the research setting into a commercially viable product, or to recognize the potential for commercialization. i3 Prism i3 Prism is an early-stage...

read more

What is the Innovation Core?

Mount Sinai’s Innovation Partners (MSIP) is the technology commercialization arm of the Mount Sinai Health System, responsible for driving the real-world application of Mount Sinai discoveries and inventions, and the development of research partnerships with industry....

read more

Newsletter Special Edition

Click here to view the special edition of the Conduit Newsletter, designed in CANVA! As part of a new initiative by The Mount Sinai ConduITS Institutes for Translational Sciences (CTSA), we are thrilled to introduce our latest newsletter designed to aid researchers in...

read more

Trainee Corner

Mount Sinai CTSA Featured Trainees

Megan Januska

Megan Januska

Megan Januska, MD is an Assistant Professor in the Division of Pediatric Pulmonology in the Jack and Lucy Clark Department of Pediatrics and in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai and Mount Sinai Kravis...

read more
Sangeetha Vadakke-Madathil

Sangeetha Vadakke-Madathil

Sangeetha Vadakke-Madathil, PhD, is currently a junior faculty (Instructor of Medicine) at Icahn School of Medicine at Mount Sinai, New York, NY. After receiving her Ph.D. degree in human hematopoietic stem cells and transplant biology from National Centre for Cell...

read more